Consensus of infectious complications in patients treated with selected biological therapies. Second part: Chilean Guidelines for Prevention of Infections associated to use of Biological Therapies (PREVITEB)

Acuna, MP

Keywords: prevention, immunocompromised host, Infection risk, clinical guideline, biological drugs

Abstract

The use of biological therapies has meant a great improvement in the management of several conditions like autoimmune, neoplastic or others diseases. Although its use has implied significant improvements in the prognosis of these diseases, it is not exempt from complications: infectious diseases as one of them. The objective of this consensus was to evaluate, from an infectious viewpoint, the safeness of the most frequently used biological therapies and give recommendations for the prevention of infections in patients treated with these drugs. These recommendations were based on the highest quality evidence available for the selected biologics. The consensus counts of 2 manuscripts. This second part is a guideline that details these recommendations through screening strategies, prophylactic therapies and vaccines indications for bacterial, mycobacterial, viral, fungal and parasitic infections, both for adults and children.

Más información

Título según WOS: Consensus of infectious complications in patients treated with selected biological therapies. Second part: Chilean Guidelines for Prevention of Infections associated to use of Biological Therapies (PREVITEB)
Título de la Revista: Revista chilena de infectología
Volumen: 36
Número: 5
Editorial: Sociedad Chilena de Infectología
Fecha de publicación: 2019
Página de inicio: 616
Página final: 628
Idioma: Spanish
Notas: ISI